Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
- PMID: 22460124
- DOI: 10.1038/nrd2909
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Abstract
The direct or indirect targeting of antibody Fc receptors (FcRs) presents unique opportunities and interesting challenges for the treatment of inflammatory diseases, cancer and infection. Biological responses induced via the Fc portions of antibodies are powerful, complex and unusual, and comprise both activating and inhibitory effects. These properties can be exploited in the engineering of therapeutic monoclonal antibodies to improve their activity in vivo. FcRs have also emerged as key participants in the pathogenesis of several important autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. Therapeutic approaches based on antagonizing FcR function with small molecules or biological drugs such as monoclonal antibodies and recombinant soluble FcR ectodomains have gained momentum. This Review addresses various strategies to manipulate FcR function to overcome immune complex-mediated inflammatory diseases, and considers approaches to improve antibody-based anticancer therapies.
Similar articles
-
The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis.Biochem Pharmacol. 2021 Jan;183:114360. doi: 10.1016/j.bcp.2020.114360. Epub 2020 Dec 7. Biochem Pharmacol. 2021. PMID: 33301760 Review.
-
Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.Expert Opin Ther Targets. 2005 Feb;9(1):169-90. doi: 10.1517/14728222.9.1.169. Expert Opin Ther Targets. 2005. PMID: 15757489 Review.
-
Targeting the Fc receptor in autoimmune disease.Expert Opin Ther Targets. 2014 Mar;18(3):335-50. doi: 10.1517/14728222.2014.877891. Expert Opin Ther Targets. 2014. PMID: 24521454 Free PMC article. Review.
-
Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.Adv Exp Med Biol. 2008;640:220-33. doi: 10.1007/978-0-387-09789-3_17. Adv Exp Med Biol. 2008. PMID: 19065795 Review.
-
Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools.Front Immunol. 2019 Apr 12;10:811. doi: 10.3389/fimmu.2019.00811. eCollection 2019. Front Immunol. 2019. PMID: 31057544 Free PMC article. Review.
Cited by
-
Induced expression of FcγRIIIa (CD16a) on CD4+ T cells triggers generation of IFN-γhigh subset.J Biol Chem. 2015 Feb 20;290(8):5127-5140. doi: 10.1074/jbc.M114.599266. Epub 2015 Jan 2. J Biol Chem. 2015. PMID: 25556651 Free PMC article. Clinical Trial.
-
Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer.Immunother Adv. 2022 May 28;2(1):ltac011. doi: 10.1093/immadv/ltac011. eCollection 2022. Immunother Adv. 2022. PMID: 36284837 Free PMC article. Review.
-
Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses.PLoS Pathog. 2016 Aug 31;12(8):e1005817. doi: 10.1371/journal.ppat.1005817. eCollection 2016 Aug. PLoS Pathog. 2016. PMID: 27579713 Free PMC article.
-
A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose.Clin Exp Immunol. 2023 Mar 8;211(1):23-30. doi: 10.1093/cei/uxac112. Clin Exp Immunol. 2023. PMID: 36480334 Free PMC article.
-
Improved HIV-positive infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts.Cell Rep Med. 2021 Apr 20;2(4):100254. doi: 10.1016/j.xcrm.2021.100254. eCollection 2021 Apr 20. Cell Rep Med. 2021. PMID: 33948582 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources